Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 20, 2011 Charly Travers	Are These the Rights You're Looking for? Consider the contingent value rights of these pharma stocks, which entitle the owner to receive cash payments if certain performance milestones are met in the future.
The Motley Fool February 4, 2008 Brian Lawler	Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note.
The Motley Fool August 30, 2010 Ryan McBride	Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams.
The Motley Fool October 28, 2010 Brian Orelli	This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37.
The Motley Fool January 4, 2008 Brian Orelli	Rabid Growth at Crucell Crucell signs a marketing agreement with Sanofi-Aventis to market Crucell's rabies treatment; who benefits more?
The Motley Fool October 4, 2010 Ryan McBride	Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share.
The Motley Fool October 4, 2010 Brian Orelli	That's No Way to Make Friends Sanofi goes hostile on Genzyme.
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
The Motley Fool October 18, 2007 Brian Lawler	Genzyme Shows Off a Drug Candidate A top compound in development could become an important MS treatment.
Chemistry World October 23, 2014 Rebecca Trager	Amgen seeks injunction to protect patents The US biopharmaceutical company Amgen has filed a patent infringement lawsuit against Sanofi and Regeneron in the US District Court of Delaware.
Chemistry World November 26, 2015 Rebecca Trager	Drug firms to share chemical compound libraries Anglo-Swedish pharmaceutical firm AstraZeneca and French drug company Sanofi have agreed to exchange 210,000 chemical compounds from their respective proprietary libraries.
Chemistry World February 17, 2011 Sarah Houlton	Sanofi to buy Genzyme in $20 billion deal Sanofi-Aventis has won its long-running battle for Genzyme, and is to acquire the US-based biotech for $74 ( 46) per share - about $20 billion in total - plus extra payments of up to $14 per share.
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
The Motley Fool July 26, 2010 Brian Orelli	Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete?
The Motley Fool December 11, 2006 Brian Lawler	Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made.
The Motley Fool August 30, 2010 Brian Orelli	Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition?
The Motley Fool December 30, 2010 Brian Orelli	2011 Drugmaker M&A Targets What Big Pharma M&A deals will 2011 hold? Most likely, more small deals, and perhaps Sanofi will finally offer a reasonable price for Genzyme. Let's take a look at some of the companies that might be walking down the aisle next year.
The Motley Fool February 20, 2007 Brian Lawler	Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
The Motley Fool October 12, 2006 Brian Lawler	Genzyme Runs a Tight Ship Revenues are up at the biopharmaceutical company, but shares dropped in morning trading.
The Motley Fool July 26, 2010 Ryan McBride	How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis
The Motley Fool September 13, 2010 Brian Orelli	When All Else Fails, Sell! Genzyme has no other choice.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
The Motley Fool February 14, 2008 Brian Lawler	Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops.
IndustryWeek October 19, 2011	FDA: A Future Innovation Partner? Could the Food and Drug Administration reform itself to help manufacturers create new medical technologies?
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Multiple Sclerosis: The Advent of the Orals The $8 billion dollar multiple sclerosis market is set to double the number of available treatments in the near future, with a dramatic switch from injectables to oral medications.
The Motley Fool August 3, 2010 Brian Orelli	Drama Continues: What's Genzyme Worth to Sanofi? Just get on with it, Sanofi and Genzyme. How much is Genzyme worth? Whatever its board of directors is willing to let it go for.
The Motley Fool September 17, 2009 Brian Orelli	Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it.
The Motley Fool January 26, 2005 Stephen D. Simpson	Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation.
The Motley Fool June 18, 2010 Brian Orelli	Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday.
The Motley Fool December 10, 2008 Brian Orelli	A Painless Advisory Panel Meeting Genzyme might be getting a Christmas present from the Food and Drug Administration. An FDA advisory panel unanimously recommended approval for Genzyme's osteoarthritis pain drug Synvisc-One.
The Motley Fool April 24, 2008 Brian Lawler	FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results.
The Motley Fool July 5, 2006 Rich Duprey	Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle.
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
The Motley Fool October 21, 2010 Brian Orelli	Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track.
Chemistry World April 24, 2008 James Mitchell Crow	FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
The Motley Fool November 18, 2008 Brian Orelli	Genzyme Grounded for Thanksgiving The biotech won't get a decision on Myozyme until February.
The Motley Fool May 26, 2010 Brian Orelli	Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme.
The Motley Fool July 27, 2007 Brian Lawler	Jumpstarting Genzyme A great quarter for Genzyme. All three of its top products had double-digit percentage sales gains; operating margins are up too.
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
The Motley Fool November 11, 2009 Brian Orelli	Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis.
The Motley Fool November 19, 2009 Brian Orelli	This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous.
The Motley Fool April 26, 2004 J. Graham	Sanofi Finally Nabs Aventis The French drug companies make a deal to merge.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
The Motley Fool February 17, 2011 Brian Orelli	What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate.
The Motley Fool September 11, 2008 Brian Lawler	Will a Change Cure Sanofi? The drugmaker charts a different course for its future.
The Motley Fool November 14, 2007 Brian Lawler	Genzyme Zigs, Shares Zag Genzyme gets downbeat news that will delay the launch of its lead drug, but shares rise. Investors, take note.
Pharmaceutical Executive July 1, 2009	French Revolution Chris Viehbacher's first fast and furious six months at the top of Sanofi-Aventis have heads spinning... and rolling.
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
The Motley Fool January 13, 2006 Stephen D. Simpson	Pfizer Pays Sanofi to Go Away Two large pharmaceutical companies settle a dispute over inhaled insulin, and $1.3 billion changes hands. Investors, take note.